INDIANAPOLIS, Feb. 22, 2007

 Eli Lilly and Company
today announced the launch of the first insulin pen with memory, HumaPen(R)
MEMOIR(TM), to help simplify the daily management of diabetes.
    (Photo: http://www.newscom.com/cgi-bin/prnh/20070222/DCTH007-a
            http://www.newscom.com/cgi-bin/prnh/20070222/DCTH007-b )
    MEMOIR is designed to meet the needs of people with diabetes who take
several shots of mealtime insulin each day. It presents sophisticated
technology and features in a consumer-friendly "push-to-know" digital
display that allows patients to record and review their last 16 insulin
doses, including the priming doses.
    Many insulin users need multiple shots per day, so the ability to
record doses and the time of the dose may help simplify the daily
management of diabetes. This is especially important for both patients and
physicians when developing a diabetes treatment plan that utilizes accurate
recording of mealtime doses. MEMOIR is now available by prescription in
pharmacies nationwide for use with Humalog(R) (insulin lispro injection
[rDNA origin]), the most-prescribed mealtime insulin in the United States.
    Lilly also announced today that it will launch an insulin pen that
delivers Humalog in smaller increments, HumaPen(R) LUXURA(TM) HD, in April
2007. LUXURA HD is a reusable pen that can deliver from 1-to-30 units of
Humalog in half-unit increments, beginning after the first unit. This type
of pen may be attractive to people with diabetes that do not need large
amounts of insulin, or parents of some children with diabetes. LUXURA HD
will require a prescription.
    Insulin pens were developed on the premise that delivery devices that
are more acceptable to patients could improve patient compliance and make a
positive contribution to long-term diabetes control. (1) Unlike traditional
insulin pens or vial and syringe, MEMOIR doesn't resemble a medical
instrument. MEMOIR, which is reusable, is sleek and designed to resemble a
writing pen, enabling the potential for more discreet injections in public
compared to using a vial and syringe.
    In a clinical study of experienced pen users, 81 percent of patients
preferred MEMOIR over the pen they were using before joining the study.
MEMOIR was considered easier and more convenient to use than the pre-study
pen and rated higher for certain pen features and most tasks related to
dosing.1 MEMOIR was developed in partnership with Battelle Medical Device
Solutions, a leader in device innovation based in Columbus, Ohio.
    Of the 21 million people with diabetes in the United States, more than
four million currently use insulin to help manage their blood sugar.
    "I see real advantages in a new tool such as MEMOIR that remembers
recent insulin doses, including the priming doses. The daily routine of
balancing meals and blood sugar readings with multiple insulin injections
can be cumbersome and overwhelming for patients," said Linda Siminerio,
PhD, assistant professor of medicine and executive director, University of
Pittsburgh Diabetes Institute; and senior vice president, International
Diabetes Federation. "Anything that helps simplify the management of this
disease and puts patients in a better position to self-manage is
beneficial."
    "As a busy college student, I'm not always thinking about how much
insulin I took at my last meal," said Reuben Bresler, a 20-year-old from
Columbus, Ohio, with type 1 diabetes and one of the first people in the
U.S. to receive a MEMOIR pen. "MEMOIR helps me keep track of my insulin
doses if I forget whether I've taken it -- or how much I took. I also like
that it looks like a writing pen instead of a medical instrument. I can
just take it out, use it and not feel self-conscious."
    Patient Needs Drive Innovation in Device Technology
    Precise meal-by-meal blood sugar management is important in diabetes
management. However, despite new treatment options that have become
available during the past few years, the American Diabetes Association's
recommended blood sugar goal -- an A1C level of less than 7 percent --
remains elusive for many with diabetes (A1C is a measure of average blood
glucose levels over a two-to-three-month period). (2) Fewer than half (43
percent) of Americans who have been diagnosed with and are being treated
for diabetes are actually achieving this A1C target. (3)
    To understand current behaviors and how specific pen features could
help patients manage their diabetes, Lilly sponsored a national,
1,000-person telephone survey4 of people with diabetes who inject insulin
at least once a day. The survey, conducted by Kelton Research in January
2007, showed that, not surprisingly, respondents were interested in new
tools that could help them better manage their disease:
    Memory can help
    -- Two-thirds of respondents said a reusable pen that tracks the date,
       time and dose of insulin would be valuable.
    -- One-third of patients reported that they forgot whether they took their
       insulin dose at least once a month; of these, 84 percent said a memory
       feature would be valuable.
    -- More than 9 in 10 (94 percent) said it is important to know if they
       missed an insulin dose.

    Looks matter too: Style and design considerations
    -- 58 percent of those surveyed said they would be interested in using an
       insulin delivery device that looked like a writing pen instead of a
       medical instrument.
    -- More than four in 10 said that a stylish looking pen would make them
       feel more comfortable injecting insulin in a public place.
    "Individuals with diabetes face unique challenges in managing this
highly complex and personal disease. Practical and innovative solutions
such as Lilly's new MEMOIR pen can help ease the management of diabetes at
mealtimes," said Matt Beebe, Humalog brand team leader, Lilly USA. "Our
goal is to help patients more accurately and discreetly manage their use of
mealtime insulin such as Humalog."
    Lilly continues to develop new insulin delivery devices to meet the
needs of people with diabetes. To learn more about Humalog and HumaPen
MEMOIR, visit Humalog.com.
    Indication
    Humalog is for use in patients with diabetes to control high blood
sugar and should be used with a longer-acting insulin, except when used in
combination with sulfonylureas in patients with type 2 diabetes.
    Important safety information for Humalog
    Humalog should not be used during episodes of hypoglycemia and in
patients sensitive to Humalog or one of its excipients. Safety and
effectiveness in patients less than three years of age have not been
established. There are no clinical studies of the use of Humalog in
pregnancy or nursing mothers. Potential side effects associated with the
use of all insulins include low blood sugar, weight gain, low blood
potassium, changes in fat tissue at the site of injection, and allergic
reactions, both general and local. Starting or changing insulin therapy
should be done cautiously and only under medical supervision.
    Humalog starts working quickly because it is absorbed quickly. That's
why you should use it at mealtime and take it within 15 minutes before or
immediately after your meal. Because Humalog is a mealtime insulin, you may
also need a longer-acting insulin to get the best blood sugar control
(except when using an insulin pump).
    For complete user instructions for HumaPen MEMOIR, please refer to the
full user manual provided with the pen. Humalog, HumaPen MEMOIR and HumaPen
LUXURA HD require a prescription.
    For additional important safety information, visit
http://www.humalog.com
    About Diabetes
    According to the Centers for Disease Control and Prevention, diabetes
affects nearly 21 million Americans; of that, nearly one-third, or
approximately six million people, do not know they have the disease.5
Diabetes is the sixth leading cause of death in the United States and costs
approximately $132 billion per year in direct and indirect medical
expenses. (5,6)
    About Lilly Diabetes
    Through a long-standing commitment to diabetes care, Lilly provides
patients with breakthrough treatments that enable them to live longer,
healthier and fuller lives. Since 1923, Lilly has been the industry leader
in pioneering therapies to help health care professionals improve the lives
of people with diabetes, and research continues on innovative medicines to
address the unmet needs of patients. Lilly also strives to recognize the
personal and professional contributions of those with and without diabetes
through the annual LillyforLife(TM) Awards. For information about the
Awards program, visit http://www.lillyforlife.com. For more information
about Lilly's diabetes products, visit http://www.lillydiabetes.com.
    About Eli Lilly and Company
    Lilly, a leading innovation-driven corporation, is developing a growing
portfolio of first-in-class and best-in-class pharmaceutical products by
applying the latest research from its own worldwide laboratories and from
collaborations with eminent scientific organizations. Headquartered in
Indianapolis, Ind., Lilly provides answers -- through medicines and
information -- for some of the world's most urgent medical needs.
Information about Lilly is available at http://www.lilly.com.
    Humalog(R) is a registered trademarks of Eli Lilly and Company.
HumaPen(R) MEMOIR(TM) and HumaPen(R) LUXURA(TM) HD are trademarks of Eli
Lilly and Company.
    B-roll is available at the times listed below

    Thursday, February 22nd, 2007
    1:30 PM - 1:45 PM ET
    G 26 (formerly IA 6)
    Transponder 11
    C-Band
    Downlink Freq: 3920 Vertical

    Thursday, February 22nd, 2007
    6:30 PM - 6:45 PM ET
    G 26 (formerly IA 6)
    Transponder 17
    C-Band
    Downlink Freq: 4040 Vertical

    Friday, February 23rd, 2007
    1:30 PM - 1:45 PM ET
    G 26 (formerly IA 6)
    Transponder 11
    C-Band
    Downlink Freq: 3920 Vertical
    Preview and access this video on Pathfire DMG: 26898. For technical
assistance call Pathfire Customer Care at 1-888-345-0489 or e-mail
support@pathfire.com
    NOTES
    (1) -- Venekamp, W. Functionality and Acceptability of a New Electronic
Insulin Injection Pen with a Memory Feature. Current Medical Research and
Opinions, 2006:22(2):315-325
    (2) -- American Diabetes Association (ADA). Standards of medical care
in diabetes. Diabetes Care. 2006 Jan;29 (Suppl 1):S8-17.
    (3) -- Saaddine JB, Engelgau MM, Beckles GL, Gregg EW, Thompson TJ,
Narayan KM. A diabetes report card for the United States: Quality of care
in the 1990s. Ann Intern Med. 2002;136:565-574.
    (4) -- The Diabetes Survey was conducted by Kelton Research between
January 8th and January 16, 2007 by telephone. Quotas are set on completed
interviews by geographic region, gender, and diabetes type, to ensure
reliable and accurate representation of the population. Results of any
sample are subject to sampling variation. The magnitude of the variation is
measurable and is affected by the number of interviews and the level of the
percentages expressing the results. In this particular study, the chances
are 95 in 100 that a survey result does not vary, plus or minus, by more
than 3.1 percentage points from the result that would be obtained if
interviews had been conducted with all persons in the universe represented
by the sample.
    (5) -- Centers for Disease Control and Prevention (CDC). National
diabetes fact sheet: general information and national estimates on diabetes
in the United States, 2005. Rev ed. Atlanta, GA: U.S. Department of Health
and Human Services, Centers for Disease Control and Prevention, 2005.
    (6) -- American Diabetes Association. Direct and indirect costs of
diabetes in the United States. Available at:
http://www.diabetes.org/diabetes- statistics/cost-of-diabetes-in-us.jsp.
Accessed January 24, 2007.